The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from CNW Group

Capital régional et coopératif Desjardins sells its interest in Enobia Pharma

Thursday, December 29, 2011

Capital régional et coopératif Desjardins sells its interest in Enobia Pharma17:01 EST Thursday, December 29, 2011MONTREAL, Dec. 29, 2011 /CNW Telbec/ - Capital régional et coopératif Desjardins (www.capitalregional.com) announces today the sale of its interest in Enobia Pharma, a firm specialized in researching therapeutic agents to treat genetic bone disorders.This sale by Capital régional et coopératif Desjardins was made in connection with the acquisition of 100% of the share capital of Enobia Pharma by Alexion Pharmaceuticals Inc. (Nasdaq : ALXN). This transaction is subject to compliance with regulatory requirements and Alexion undertakes to complete it for a total amount of $1.08 billion in cash, of which $610 million is payable at the time of the transaction slated for the first quarter of 2012 and $470 million is payable on achievement of certifications and performance objectives.With this transaction, Capital régional et coopératif Desjardins should realize a gain on sale proceeds representing a positive impact on its share value of over $0.35 for the second half of 2011. Additional gains could be realized based on achievement of various financial and scientific milestones staggered over the next few years.For Marie-Claude Boisvert, Chief Operating Officer of Desjardins Venture Capital, the manager of Capital régional et coopératif Desjardins, the partnership with Enobia Pharma yielded results today. "We're proud to have been associated with a company that stayed the course and demonstrated an uncanny ability to make a name for itself in a complex, highly regulated market. And we share these very positive results with our 107,000 shareholders.""We're delighted to see Enobia complete this strategic transaction and have enjoyed working closely with them in developing therapeutics that will be of great benefit to many patients," said Torsten Goesch, Partner, Rosetta Capital Limited, a partner of Desjardins Venture Capital and manager of Capital régional et coopératif Desjardins' life sciences portfolio.About Capital régional et coopératif DesjardinsCapital régional et coopératif Desjardins, this year celebrating its 10th anniversary, is a publicly traded company managed by Desjardins Venture Capital. With over 107,000 shareholders and net assets of $1,082 million, the company contributes to Québec's economic development while driving the growth of cooperatives and the resource regions. Capital régional et coopératif Desjardins currently supports more than 220 companies, cooperatives and funds in various industries spanning all Québec regions. (www.capitalregional.com)About Enobia Pharma Corp.Enobia Pharma Corp., based in Montreal, Canada, and Cambridge, Massachusetts, is a privately held clinical stage biotech company focused on developing novel therapeutics for serious metabolic bone disorders. The Company's largest investors include OrbiMed, Fonds de Solidarité des Travailleurs du Québec (F.T.Q.), Capital régional et coopératif Desjardins, CTI Life Sciences Fund, L.P., and Lothian Partners 27 (Sarl) SICAR. For more information, please visit www.enobia.com.About Rosetta Capital LimitedHeadquartered in the United Kingdom, Rosetta Capital is a multinational specialist venture capital firm focused on the life science and medical technology sectors. It manages a venture capital portfolio of primary and secondary venture capital investments comprising more than 25 companies across Europe and North America. The firm has been active in Canada since the beginning of 2000; in 2008, it signed an agreement for the management of Capital régional et coopératif Desjardins' life sciences portfolio. (www.rosettacapital.com)Forward-looking statements and disclaimerThis press release includes forward-looking statements that involve risks and uncertainties. These forward-looking statements mainly relate to the completion of the above described transaction and the related potential gain. They can generally be identified by the use of words such as "can" and "expect," including the negatives of these terms or variations of them or similar terminology. Although Capital régional et coopératif Desjardins (the "Company") believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to be correct. Forward-looking statements do not reflect the potential impact on the Company's business of special items announced or occurring after the statements are made.Investors and others are cautioned that undue reliance should not be placed on any forward-looking statements. For more information on the risks, uncertainties and assumptions that would cause the Company's actual results to differ from current expectations, please refer to the Company's public filings available on its website and on the SEDAR website at www.sedar.com.The forward-looking statements in this press release reflect the Company's expectations as at December 29, 2011, and are subject to change after this date. The Company expressly disclaims any obligation or intention to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by the applicable securities laws.For further information: (for journalists only): Francine Blackburn Capital régional et coopératif Desjardins 514 281-7000, ext. 7544 -- 1 866 866-7000, ext. 7544 media@desjardins.com